[go: up one dir, main page]

PE20140890A1 - Derivados de isoxazolidina - Google Patents

Derivados de isoxazolidina

Info

Publication number
PE20140890A1
PE20140890A1 PE2013002015A PE2013002015A PE20140890A1 PE 20140890 A1 PE20140890 A1 PE 20140890A1 PE 2013002015 A PE2013002015 A PE 2013002015A PE 2013002015 A PE2013002015 A PE 2013002015A PE 20140890 A1 PE20140890 A1 PE 20140890A1
Authority
PE
Peru
Prior art keywords
halogen
hydroxy
dimethyl
independently
refers
Prior art date
Application number
PE2013002015A
Other languages
English (en)
Inventor
Eleonora Ghidini
Andrea Rizzi
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44351355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140890(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of PE20140890A1 publication Critical patent/PE20140890A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0036—Nitrogen-containing hetero ring
    • C07J71/0057—Nitrogen and oxygen
    • C07J71/0068—Nitrogen and oxygen at position 16(17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

SE REFIERE A UN COMPUESTO DE FORMULA (I) DONDE: R1 ES (CH2)n-Z-(CH2)n�-R3, DONDE n Y n� SON INDEPENDIENTEMENTE 0, 1 O 2; Z ES UNA UNION SIMPLE O SE SELECCIONA ENTRE S, O, Y OC(R4R5), R3 ES H, HALOGENO, CN, OH, ENTRE OTROS; R2 ES (C1-C8)ALQUILO LINEAL O RAMIFICADO, (C1-C6)ALCOXI, (C1-C6)HALOALQUILO OPCIONALMENTE SUSTITUIDO CON UNO O MAS GRUPOS CN O ATOMOS DE HALOGENO, ENTRE OTROS; X E Y SON INDEPENDIENTEMENTE H O HALOGENO, CON LA CONDICION QUE CUANDO R1 ES UN GRUPO CH2OH Y R2 ES (C1-C6)ALQUILO O (C3-C8)CICLOALQUILO, LUEGO X E Y SON ATOMOS DE FLUOR. ES UN COMPUESTO PREFERIDO: (4aS,4bR,5S,6aS,6bR,9aS,10aS,10bS,12S)-8-(3,3-DIMETIL-BUTIL)-4b,12-DIFLUORO-5-HIDROXI-6b-(2-HIDROXI-ACETIL)-4a,6a-DIMETIL-4a,4b,5,6,6a,6b,8,9,9a,10,10a,10b,11,12-TETRADECAHIDRO-7-OXA-8-AZA-PENTALEN[2,1-a]FENANTREN-2-ONA; ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA
PE2013002015A 2011-03-15 2012-03-14 Derivados de isoxazolidina PE20140890A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP11158230 2011-03-15

Publications (1)

Publication Number Publication Date
PE20140890A1 true PE20140890A1 (es) 2014-08-05

Family

ID=44351355

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013002015A PE20140890A1 (es) 2011-03-15 2012-03-14 Derivados de isoxazolidina

Country Status (23)

Country Link
US (3) US20120234316A1 (es)
EP (2) EP2686332A2 (es)
JP (1) JP6053700B2 (es)
KR (1) KR101956937B1 (es)
CN (1) CN103391945B (es)
AR (1) AR085817A1 (es)
AU (1) AU2012228334B2 (es)
BR (1) BR112013023539B1 (es)
CA (1) CA2850081C (es)
CL (1) CL2013002629A1 (es)
EA (1) EA028904B1 (es)
GE (1) GEP201606566B (es)
IL (1) IL228382A (es)
MX (1) MX345400B (es)
MY (1) MY194140A (es)
PE (1) PE20140890A1 (es)
PH (1) PH12013501813A1 (es)
SG (1) SG193262A1 (es)
TN (1) TN2013000313A1 (es)
TW (1) TWI658047B (es)
UA (1) UA113508C2 (es)
WO (1) WO2012123482A2 (es)
ZA (2) ZA201306881B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103814043A (zh) 2011-08-01 2014-05-21 奇斯药制品公司 在16，17位与吡咯烷环稠合的抗炎类固醇
US9155747B2 (en) * 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives
EP2902382A1 (en) * 2014-01-30 2015-08-05 Fundació Institut de Recerca Biomèdica IRB (Barcelona) Primary hydroxylamines and uses thereof
SI3662910T1 (sl) * 2014-03-31 2025-05-30 The Scripps Research Institute Farmakofor za induciranje TRAIL
CN113332439A (zh) 2014-09-03 2021-09-03 理森制药股份公司 包含双重PI3Kδ-γ激酶抑制剂和皮质类固醇的治疗方法及组合物
CN104262440B (zh) * 2014-09-10 2016-08-17 江西赣亮医药原料有限公司 一种16ɑ-羟基泼尼松龙的制备方法
CN117050128A (zh) * 2023-08-15 2023-11-14 黄冈人福药业有限责任公司 一种11β-羟基-孕甾-1,4,16-三烯-3,20-二酮-21-醋酸酯的制备方法和设备
CN118638008B (zh) * 2024-08-14 2024-12-17 淄博飞源化工有限公司 甲基丙烯酸三氟乙酯及其合成方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL31997A (en) * 1968-05-03 1974-03-14 Lepetit Spa Process for the preparation of pregnano(17alpha,16alpha-d)oxazolines and 16alpha,21-dihydroxy-17alpha-aminopregnanes
US4018774A (en) 1976-02-13 1977-04-19 E. R. Squibb & Sons, Inc. Steroidal [16α,17-d]isoxazolidines
AR224124A1 (es) * 1978-04-05 1981-10-30 Syntex Inc Procedimiento para preparar 4-halo-pregna-1,4-dieno-3,20-dionas
WO2005028495A1 (en) * 2003-09-24 2005-03-31 Glaxo Group Limited Anti-inflammatory glucocorticoids
GB0415747D0 (en) * 2004-07-14 2004-08-18 Novartis Ag Organic compounds
JP2008526776A (ja) 2005-01-03 2008-07-24 ミリアド ジェネティクス， インコーポレイテッド 脳癌の治療の方法
EA201070535A1 (ru) * 2007-11-30 2010-12-30 Пфайзер Лимитед Новые агонисты глюкокортикоидных рецепторов
WO2009108118A1 (en) * 2008-02-27 2009-09-03 Astrazeneca Ab 16 alpha, 17 alpa-acetal glucocorticosteroidal derivatives and their use
CN101926805A (zh) * 2009-06-24 2010-12-29 天津金耀集团有限公司 一种含有16,17异恶唑烷类甾体化合物的药物组合物
PE20120894A1 (es) * 2009-09-11 2012-08-13 Chiesi Farma Spa Derivados de isoxazolidina
TW201139369A (en) * 2010-02-05 2011-11-16 Chiesi Farma Spa Pyrrolidine derivatives
KR20140039161A (ko) 2011-03-15 2014-04-01 키에시 파르마슈티시 엣스. 피. 에이. 이소옥사졸리딘 유도체
CN103814043A (zh) 2011-08-01 2014-05-21 奇斯药制品公司 在16，17位与吡咯烷环稠合的抗炎类固醇
US9155747B2 (en) 2012-09-13 2015-10-13 Chiesi Farmaceutici S.P.A. Isoxazolidine derivatives

Also Published As

Publication number Publication date
TN2013000313A1 (en) 2015-01-20
PH12013501813A1 (en) 2013-10-14
KR20140006016A (ko) 2014-01-15
TW201247697A (en) 2012-12-01
IL228382A (en) 2017-08-31
MY194140A (en) 2022-11-14
MX345400B (es) 2017-01-30
TWI658047B (zh) 2019-05-01
ZA201306881B (en) 2014-11-26
CA2850081A1 (en) 2012-09-20
IL228382A0 (en) 2013-12-31
AU2012228334A1 (en) 2013-10-03
EA028904B1 (ru) 2018-01-31
US20120234316A1 (en) 2012-09-20
MX2013010354A (es) 2013-12-06
EP2686332A2 (en) 2014-01-22
AR085817A1 (es) 2013-10-30
NZ615423A (en) 2015-08-28
WO2012123482A2 (en) 2012-09-20
EP2716648B1 (en) 2017-06-14
JP2014508181A (ja) 2014-04-03
AU2012228334B2 (en) 2017-03-23
CN103391945A (zh) 2013-11-13
BR112013023539A2 (pt) 2017-01-24
UA113508C2 (xx) 2017-02-10
ZA201405681B (en) 2015-12-23
EA201391173A1 (ru) 2014-01-30
GEP201606566B (en) 2016-11-10
US20150057257A1 (en) 2015-02-26
SG193262A1 (en) 2013-10-30
EP2716648A1 (en) 2014-04-09
US10280193B2 (en) 2019-05-07
JP6053700B2 (ja) 2016-12-27
CN103391945B (zh) 2016-11-09
CA2850081C (en) 2020-01-07
US20180066010A1 (en) 2018-03-08
US9845337B2 (en) 2017-12-19
KR101956937B1 (ko) 2019-03-11
CL2013002629A1 (es) 2014-01-10
WO2012123482A3 (en) 2013-02-07
BR112013023539B1 (pt) 2022-03-03

Similar Documents

Publication Publication Date Title
PE20140890A1 (es) Derivados de isoxazolidina
AR122552A2 (es) Composición acuosa de inmunoglobulina estable durante el almacenamiento y método para estabilizar una composición de inmunoglobulina
CO2021015698A2 (es) Moduladores de thr-β y métodos de uso de estos
ECSP12012292A (es) Ciertas amino-piridazinas, composicioines de las mismas y métodos de uso de los mismos
ECSP12012293A (es) Ciertas amino-pirimidinas, composicioines de las mismas y métodos para el uso de los mismos
MX2016001732A (es) Compuestos de benzoxaborol triciclicos y usos de los mismos.
MX2017010062A (es) [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2 ,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos.
BR112015005891A2 (pt) método de sintetizar análogos do hormônio da tireoide e polimorfos destes
PE20150627A1 (es) Derivados de c17-alcandiilo y alquendiilo del acido oleanolico y sus metodos de uso
MX2014002770A (es) Nuevos derivados dihidroquinolina-2-ona.
CO2018003134A2 (es) Composiciones para el cuidado bucal que comprenden un aminoácido básico, una combinación de fuentes de iones de zinc y un sistema quelante
PE20180483A1 (es) Oxiesteroles y metodos de uso de los mismos
AR086837A1 (es) Moduladores heterociclicos de sintesis lipidica
UY35641A (es) PROCEDIMIENTO DE SÍNTESIS PARA PREPARAR ANÁLOGOS MACROCÍCLICOS C1-CETO DE HALICONDRINA B, E INTERMEDIARIOS ÚTILES INCLUYENDO INTERMEDIARIOS CONTENIENDO GRUPOS ?SO2-(p-TOLILO)
AR072016A1 (es) Derivados de isoxazol que funcionan como potenciadores de los receptores de glutamato
PE20151939A1 (es) 3-pirimidin-4-il-oxazolidin-2-onas como inhibidores de idh mutante
BR112014015935A2 (pt) composição de agentes de detecção de células tumorais epiteliais e seu método de preparação
AR077701A1 (es) Compuestos antiproliferativos, conjugados de los mismos, procedimientos para estos, y usos de los mismos
AR105592A1 (es) b-AMINOÁCIDOS b-SUSTITUIDOS Y ANÁLOGOS COMO AGENTES QUIMIOTERAPÉUTICOS Y USOS DE LOS MISMOS
PE20151995A1 (es) Compuestos sustituidos de pirrolopirimidina, composiciones de los mismos, y metodos de tratamiento con los mismos
PE20120894A1 (es) Derivados de isoxazolidina
CL2012001961A1 (es) Método para tratar una enfermedad o trastorno en que aumentan los niveles de hormonas de estrés y/o disminuyen los niveles de hormonas de andrógenos, en que se administra un compuesto pirrolo-[1,2-c]-imidazol-bencil sustituido; su uso en insuficiencia cardíaca, entre otros; y compuestos pirrolo-[1,2-c]-imidazol-bencil sustituidos.
MX2019002915A (es) Derivado de ?-aminoacido triciclico fusionado, metodo de preparacion, y su uso medico del mismo.
CL2017002060A1 (es) Compuestos de benzoxaborol y usos de los mismos
CL2023002429A1 (es) Derivados novedosos de pirimidin-2-il sulfonamida

Legal Events

Date Code Title Description
FG Grant, registration